Hyphen Pharma International - CGS-CIMB Research 2022-01-06: On The Lookout For Growth

Hyphen Pharma International - On The Lookout For Growth

HYPHENS PHARMA INTL LIMITED (SGX:1J5) | SGinvestors.ioHYPHENS PHARMA INTL LIMITED (SGX:1J5)
  • We initiate coverage on Hyphens Pharma (SGX:1J5) with an ADD rating and a DCF-derived target price of S$0.36 (WACC: 9.4%) post its acquisition of Novem.
  • We like Hyphens Pharma for its resilient business model and growing product portfolio as well as sales and distribution channels that will drive future earnings growth.
  • Re-rating catalysts: accretive portfolio acquisitions and positive Ceradan patent applications.
  • Key risks: movement restrictions in medical channels.
  • We believe that Hyphens Pharma's share price has yet to reflect the value of its business acquisition of Novem, the first since its listing. Hyphens Pharma currently trades at 11.1x FY22F P/E, close to 1 standard deviation below its historical mean.



Above is the excerpt from research report by CGS-CIMB.
Clients of CGS-CIMB may access the full report in PDF @ https://www.itradecimb.com.sg/.



TAY Wee Kuang CGS-CIMB Research | https://www.cgs-cimb.com 2022-01-06
SGX Stock Analyst Report ADD INITIATE ADD 0.36 SAME 0.36




Target prices by 2 other brokers at Hyphens Pharma Target Prices.
Listing of broker reports at Hyphens Pharma Analyst Report.

Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividends & Corp Actions,
Hyphens Pharma News Articles





Advertisement










Stock / REIT Search

Advertisement

Advertisement